MCID: PLS037
MIFTS: 23

Plasma Cell Tumor

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Plasma Cell Tumor

MalaCards integrated aliases for Plasma Cell Tumor:

Name: Plasma Cell Tumor 59

Classifications:



External Ids:

UMLS via Orphanet 73 C1136084 C1959632
Orphanet 59 ORPHA98282

Summaries for Plasma Cell Tumor

MalaCards based summary : Plasma Cell Tumor is related to plasmacytoma and myeloma, multiple. An important gene associated with Plasma Cell Tumor is IGKC (Immunoglobulin Kappa Constant). The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, b cells and t cells.

Wikipedia : 75 Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within... more...

Related Diseases for Plasma Cell Tumor

Graphical network of the top 20 diseases related to Plasma Cell Tumor:



Diseases related to Plasma Cell Tumor

Symptoms & Phenotypes for Plasma Cell Tumor

Drugs & Therapeutics for Plasma Cell Tumor

Drugs for Plasma Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
3
Nelfinavir Approved Phase 1, Phase 2 159989-64-7 64143
4
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
5 Immunologic Factors Phase 1, Phase 2
6 Hormone Antagonists Phase 1, Phase 2
7 HIV Protease Inhibitors Phase 1, Phase 2
8 Antiemetics Phase 1, Phase 2
9 Anti-Inflammatory Agents Phase 1, Phase 2
10
protease inhibitors Phase 1, Phase 2
11 Gastrointestinal Agents Phase 1, Phase 2
12 Angiogenesis Inhibitors Phase 1, Phase 2
13 glucocorticoids Phase 1, Phase 2
14 Hormones Phase 1, Phase 2
15 Peripheral Nervous System Agents Phase 1, Phase 2
16 Angiogenesis Modulating Agents Phase 1, Phase 2
17 Anti-Infective Agents Phase 1, Phase 2
18 Antineoplastic Agents, Hormonal Phase 1, Phase 2
19 Anti-HIV Agents Phase 1, Phase 2
20 Autonomic Agents Phase 1, Phase 2
21 Antiviral Agents Phase 1, Phase 2
22 BB 1101 Phase 1, Phase 2
23 Anti-Retroviral Agents Phase 1, Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
25 Vaccines Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial Active, not recruiting NCT01555281 Phase 1, Phase 2 Nelfinavir;Lenalidomide;Dexamethasone
2 The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma Completed NCT00459069 Phase 1
3 Quality of Life in Patients With Multiple Myeloma Completed NCT00290095

Search NIH Clinical Center for Plasma Cell Tumor

Genetic Tests for Plasma Cell Tumor

Anatomical Context for Plasma Cell Tumor

MalaCards organs/tissues related to Plasma Cell Tumor:

41
Bone, B Cells, T Cells, Bone Marrow, Lung, Spleen, Thymus

Publications for Plasma Cell Tumor

Articles related to Plasma Cell Tumor:

(show top 50) (show all 247)
# Title Authors PMID Year
1
Primary plasmablastic plasmacytoma in the stomach of an immunocompetent adult: A case report. 38
30681607 2019
2
Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma. 38
30563570 2018
3
Total En Bloc Spondylectomy for Lumbar Spinal Tumors by Paraspinal Approach. 38
30144592 2018
4
Tonsillar plasmacytoma in a dog. 38
30104774 2018
5
Anaplastic plasmacytoma: a rare tumor presenting as a pathological fracture in a younger adult. 38
29388036 2018
6
Targeting MYC in multiple myeloma. 38
29467490 2018
7
Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. 38
29783691 2018
8
Autologous tumor cells/bacillus Calmette-Guérin/formalin-based novel breast cancer vaccine induces an immune antitumor response. 38
29755647 2018
9
A Case of Concurrent Gastric and Pancreatic Plasmacytomas in a Patient With Multiple Myeloma: An Extremely Rare Entity. 38
29854857 2018
10
Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. 38
28886236 2017
11
Current treatment options of T cell-associated immunotherapy in multiple myeloma. 38
28120217 2017
12
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. 38
28052011 2017
13
Proceedings of the 2016 National Toxicology Program Satellite Symposium. 38
27821709 2017
14
Revisiting IL-6 antagonism in multiple myeloma. 38
27497026 2016
15
Cytology of plasma cell rich effusion in cases of plasma cell neoplasm. 38
27756988 2016
16
Extramedullary Plasmacytoma Mimicking Pancreatic Cancer: An Unusual Presentation. 38
27847663 2016
17
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. 38
26496024 2016
18
Resident Rounds: Part III--Case Report: Metastatic Multiple Myeloma. 38
26741539 2015
19
Plasmacytoma to the Axis Mimicking Metastatic Paraganglioma: Circumferential Reconstruction via Posterior Approach. 38
26834819 2015
20
The tumor microenvironment shapes hallmarks of mature B-cell malignancies. 38
25639873 2015
21
Osseous plasma cell neoplasm of the mandible for initial diagnosis of multiple myeloma: case report and literature review. 38
25861199 2015
22
Non-secreting multiple myeloma switches to IgD of lamda type: a case report and review of literature. 38
26629254 2015
23
Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma. 38
25995641 2015
24
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature. 38
26464727 2015
25
The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. 38
25257990 2015
26
In vivo models of multiple myeloma (MM). 38
24704250 2014
27
Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. 38
25272036 2014
28
Cyberknife radiosurgery for cranial plasma cell tumor. 38
24831374 2014
29
Diffuse Hepatic and Spleen Uptake of Tc-99m MDP on Bone Scintigraphy Resembling Liver-Spleen Scintigraphy in a Patient of Plasma Cell Tumor. 38
24795828 2014
30
Plasma cell neoplasms presenting with masses: a study on morphology, expression of CD56 and cyclin D1, and presence of Epstein-Barr virus in 39 Thai patients in SiriraJ Hospital. 38
24511724 2013
31
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. 38
24292417 2013
32
Intravitreal bevacizumab for ocular metastasis of multiple myeloma. 38
23811608 2013
33
Lumbar hemangioma masking a plasma cell tumor--case report and review of the literature. 38
23562558 2013
34
Extramedullary nasal plasmacytoma: Literature review and a rare case report. 38
25992016 2013
35
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. 38
23044976 2013
36
Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats. 38
22772480 2012
37
Solitary plasmacytoma of the tonsillar site associated with actinomyces infection: the possible role of IL-6. 38
23034278 2012
38
NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. 38
22642622 2012
39
Plasma cell tumor of the clivus: report of two cases. 38
22644013 2012
40
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. 38
22147894 2012
41
Multiple myeloma: a clinical overview. 38
25188477 2011
42
What is your diagnosis? Plasma cell tumor. 38
21961629 2011
43
Ocular manifestations of multiple myeloma: three cases and a review of the literature. 38
21193351 2011
44
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. 38
21173094 2011
45
Extranodal testicular anaplastic versus plasmablastic plasma cell tumor: A rare case with diagnostic dilemma in a developing country. 38
21731218 2011
46
Extramedullary plasmacytoma of the tonsil. 38
22937367 2011
47
Multiple myeloma presenting as solitary mass in the posterior fossa. 38
20727769 2010
48
Pathology in practice. Diagnosis: Multicentric plasma cell tumor (multiple myeloma [MM]). 38
20946077 2010
49
[Morphologic diversity of plasma cell neoplasms]. 38
21055031 2010
50
An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region. 38
18846427 2010

Variations for Plasma Cell Tumor

Expression for Plasma Cell Tumor

Search GEO for disease gene expression data for Plasma Cell Tumor.

Pathways for Plasma Cell Tumor

GO Terms for Plasma Cell Tumor

Sources for Plasma Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....